Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Pacad Investment Ltd.

Pacad Investment Ltd. lessened its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 37.5% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,500 shares of the biopharmaceutical company’s stock after selling 3,900 shares during the period. Pacad Investment Ltd.’s holdings in Ultragenyx Pharmaceutical were worth $404,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of RARE. Sei Investments Co. bought a new stake in shares of Ultragenyx Pharmaceutical in the 2nd quarter worth $125,000. Pacer Advisors Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 22.6% in the 1st quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 560 shares in the last quarter. Strs Ohio increased its holdings in shares of Ultragenyx Pharmaceutical by 10.7% in the 1st quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 300 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 3.7% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock worth $219,000 after purchasing an additional 115 shares in the last quarter. Finally, Tocqueville Asset Management L.P. increased its holdings in shares of Ultragenyx Pharmaceutical by 8.0% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after purchasing an additional 250 shares in the last quarter. 96.18% of the stock is owned by institutional investors.

A number of equities analysts have recently issued reports on RARE shares. Canaccord Genuity set a $98.00 price target on Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a research note on Friday, July 28th. Stifel Nicolaus restated a “buy” rating and issued a $111.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, June 30th. BidaskClub upgraded Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. J P Morgan Chase & Co set a $76.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Wednesday, August 23rd. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $69.00 target price (down from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, August 23rd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company. Ultragenyx Pharmaceutical has a consensus rating of “Hold” and an average target price of $71.65.

In other news, CEO Emil D. Kakkis acquired 7,500 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, August 28th. The shares were acquired at an average price of $52.52 per share, with a total value of $393,900.00. Following the completion of the purchase, the chief executive officer now owns 430,569 shares of the company’s stock, valued at approximately $22,613,483.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 9.20% of the company’s stock.

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) opened at 53.39 on Friday. The firm’s 50-day moving average price is $57.68 and its 200 day moving average price is $63.99. The company’s market capitalization is $2.27 billion. Ultragenyx Pharmaceutical Inc. has a 52 week low of $49.56 and a 52 week high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.73) by $0.01. During the same quarter in the previous year, the company posted ($1.46) earnings per share. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post ($7.21) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Pacad Investment Ltd.” was first published by BBNS and is the property of of BBNS. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://baseballnewssource.com/markets/pacad-investment-ltd-has-404000-position-in-ultragenyx-pharmaceutical-inc-rare/1600888.html.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Fans Kicked Out of Fenway Park After Racist Banner Hung on Green Monster
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Dodgers End Losing Streak at 11 Behind Ace Clayton Kershaw
Cleveland Indians Winning Streak Reaches 18
Cleveland Indians Winning Streak Reaches 18


Leave a Reply

 
© 2006-2017 BBNS.